Taiwan · Delayed Price · Currency is TWD Welgene Biotech Statistics
Total Valuation
Welgene Biotech has a market cap or net worth of TWD 434.62 million. The enterprise value is 398.10 million.
| Market Cap | 434.62M |
| Enterprise Value | 398.10M |
Important Dates
The next estimated earnings date is Friday, May 8, 2026.
| Earnings Date | May 8, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Welgene Biotech has 23.30 million shares outstanding. The number of shares has decreased by -4.88% in one year.
| Current Share Class | 23.30M |
| Shares Outstanding | 23.30M |
| Shares Change (YoY) | -4.88% |
| Shares Change (QoQ) | -19.52% |
| Owned by Insiders (%) | 8.40% |
| Owned by Institutions (%) | n/a |
| Float | 7.19M |
Valuation Ratios
The trailing PE ratio is 326.79.
| PE Ratio | 326.79 |
| Forward PE | n/a |
| PS Ratio | 1.16 |
| PB Ratio | 1.52 |
| P/TBV Ratio | 1.55 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 12.32 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.29, with an EV/FCF ratio of -65.53.
| EV / Earnings | 299.32 |
| EV / Sales | 1.06 |
| EV / EBITDA | 14.29 |
| EV / EBIT | n/a |
| EV / FCF | -65.53 |
Financial Position
The company has a current ratio of 2.21, with a Debt / Equity ratio of 0.79.
| Current Ratio | 2.21 |
| Quick Ratio | 1.92 |
| Debt / Equity | 0.79 |
| Debt / EBITDA | 8.11 |
| Debt / FCF | -37.29 |
| Interest Coverage | 0.04 |
Financial Efficiency
Return on equity (ROE) is 0.45% and return on invested capital (ROIC) is 0.06%.
| Return on Equity (ROE) | 0.45% |
| Return on Assets (ROA) | 0.01% |
| Return on Invested Capital (ROIC) | 0.06% |
| Return on Capital Employed (ROCE) | 0.03% |
| Weighted Average Cost of Capital (WACC) | 4.33% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.65 |
| Inventory Turnover | 5.79 |
Taxes
In the past 12 months, Welgene Biotech has paid 42,000 in taxes.
| Income Tax | 42,000 |
| Effective Tax Rate | 3.14% |
Stock Price Statistics
The stock price has decreased by -3.37% in the last 52 weeks. The beta is 0.29, so Welgene Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.29 |
| 52-Week Price Change | -3.37% |
| 50-Day Moving Average | 18.81 |
| 200-Day Moving Average | 19.69 |
| Relative Strength Index (RSI) | 50.35 |
| Average Volume (20 Days) | 7,228 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Welgene Biotech had revenue of TWD 375.94 million and earned 1.33 million in profits. Earnings per share was 0.06.
| Revenue | 375.94M |
| Gross Profit | 156.18M |
| Operating Income | 127,000 |
| Pretax Income | 1.34M |
| Net Income | 1.33M |
| EBITDA | 27.92M |
| EBIT | 127,000 |
| Earnings Per Share (EPS) | 0.06 |
Balance Sheet
The company has 267.33 million in cash and 226.53 million in debt, with a net cash position of 40.80 million or 1.75 per share.
| Cash & Cash Equivalents | 267.33M |
| Total Debt | 226.53M |
| Net Cash | 40.80M |
| Net Cash Per Share | 1.75 |
| Equity (Book Value) | 286.07M |
| Book Value Per Share | 15.00 |
| Working Capital | 199.43M |
Cash Flow
In the last 12 months, operating cash flow was 35.27 million and capital expenditures -41.34 million, giving a free cash flow of -6.08 million.
| Operating Cash Flow | 35.27M |
| Capital Expenditures | -41.34M |
| Depreciation & Amortization | 27.79M |
| Net Borrowing | 51.31M |
| Free Cash Flow | -6.08M |
| FCF Per Share | -0.26 |
Margins
Gross margin is 41.54%, with operating and profit margins of 0.03% and 0.35%.
| Gross Margin | 41.54% |
| Operating Margin | 0.03% |
| Pretax Margin | 0.36% |
| Profit Margin | 0.35% |
| EBITDA Margin | 7.43% |
| EBIT Margin | 0.03% |
| FCF Margin | n/a |
Dividends & Yields
Welgene Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 4.88% |
| Shareholder Yield | 4.88% |
| Earnings Yield | 0.31% |
| FCF Yield | -1.40% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on August 17, 2018. It was a forward split with a ratio of 1.08.
| Last Split Date | Aug 17, 2018 |
| Split Type | Forward |
| Split Ratio | 1.08 |
Scores
Welgene Biotech has an Altman Z-Score of 1.91 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.91 |
| Piotroski F-Score | 5 |